The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Insights into evolving mortality trends in multiple myeloma: findings from a SEER analysis
In this video, Shahzad Raza, MD, Cleveland Clinic, Cleveland, OH, briefly discusses an analysis that used the SEER database to investigate the evolving mortality trends in multiple myeloma (MM). Dr Raza highlights that patients who survive beyond three years may now succumb to cardiovascular and infectious diseases rather than multiple myeloma itself, underscoring the need for robust survivorship programs to address the complex medical issues faced by patients living longer with the disease. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
